Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Positive Lymphoid Tumors - Infusion-of-CAR-NK-Cells

Unlock the potential of CAR-transduced natural killer (NK) cells in treating CD19-positive lymphoid tumors with our latest study. Explore the infusion of CAR-NK cells derived from cord blood, showing promising responses in patients with relapsed non-Hodgkin’s lymphoma or chronic lymphocytic leukemia. Discover how HLA-mismatched anti-CD19 CAR-NK cells, manufactured from cord blood, triggered positive treatment responses without significant toxic effects. Delve into the methodology behind the manufacture of CAR-NK cells and the treatment process involving lymphodepleting chemotherapy followed by CAR-NK cell infusion. Uncover the remarkable safety profile of CAR-NK cell therapy, with no instances of cytokine release syndrome, neurotoxicity, or graft-versus-host disease observed. Dive into the results, showcasing objective responses in 73% of patients, including complete responses in 7 patients with CLL or lymphoma. Witness the potential of CAR-NK cells in inducing responses in high-risk CD19-positive cancers with minimal adverse events.

Next-generation cell therapies: the emerging role of CAR-NK cells

Next-generation cell therapies: the emerging role of CAR-NK cells Receptors in Detail Summary T cells with chimeric antigen receptors (CARs) have transformed cell therapy and shifted the treatment paradigm for many patients with recurrent or refractory B-cell malignancies. Despite this advancement, CAR-T cell treatment has limits in both autologous and allogeneic contexts, including practical, logistical, […]

CAR NK therapy attacks cancer quickly

CAR NK therapy offers experimental treatment option Overall Survival Summary Natural killer cells – or NK cells – are part of our immune system. They patrol our bodies for abnormal cells like cancer and destroy them. But cancer cells can make themselves invisible, making it much more difficult for NK cells to find them and […]

CAR-NK cells: A promising cellular immunotherapy for cancer

CAR-NK cells: A promising cellular immunotherapy for cancer Overall Survival Summary Natural Killer (NK) cells and CD8+ cytotoxic T cells are two types of immune cells that can kill target cells through similar cytotoxic mechanisms. With the remarkable success of chimeric antigen receptor (CAR)- engineered T (CAR-T) cells for treating haematological malignancies, there is a […]

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy Summary Natural killer (NK) cells are specialized immune cells that can be genetically manipulated to produce capable effector cells for adoptive cellular therapy of cancer patients due to their rapid detection and lysis of malignant cells. However, biological and technical barriers to […]

Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany

Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany Chimeric Antigen Receptors Summary Chimeric antigen receptor-T cell therapies are poised to become powerful immunotherapeutic tools for combating hematological diseases, which have a pressing need for treatment. Patients characteristics Recently, CAR-NK cell therapy has also come be the focus of new treatment options […]

Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines

Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines Patient derived Melanoma Cell Lines Summary We describe the development, optimization, and validation of 384-well growth inhibition assays for six patient-derived melanoma cell lines (PDMCLs), three wild type (WT) for BRAF and three with V600E-BRAF mutations. We conducted a pilot drug combination (DC) high-throughput […]

Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany

Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany Summary CAR-NK cell therapies have risen to prominence as a unique therapeutic alternative for overcoming challenges associated with CAR-T cell therapies, such as therapy-induced side effects. More than 500 CAR-T and 17 CAR-NK cell trials are currently underway around the world, including […]

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy

Chimeric antigen receptor

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy Summary Due to their efficient recognition and lysis of malignant cells, natural killer (NK) cells are considered as specialized immune cells that can be genetically modified to obtain capable effector cells for adoptive cellular treatment of cancer patients. Recent technological advancements, including […]

Viju

Viju (UK) Appendiceal cancer This statement was given by a family member of the patient: My wife successfully had her samples collected to be dispatched. We met with the nurses, Mikaela and a colleague, they were very helpful, professional and caring. Everything went smoothly and my wife was very content. We thank the whole team […]